WHO grants emergency use listing for Bharat Biotech’s Covaxin

Aditi Tandon
Tribune News Service
New Delhi, November 3

The World Health Organization’s technical advisory group meet on Wednesday and approved for emergency use listing of India’s indigenous Covid 19 vaccine, Covaxin.

Covaxin has become the seventh vaccine to get WHO approval.

The technical advisory group had on October 26 nee to consider emergency use listing for Covaxin and sought additional clarifications.

The WHO had been working closely with Bharat Biotech to complete the dossier.

WHO chief scientist Soumya Swaminathan said that the WHO’s goal was to have a broad portfolio of vaccines approved for emergency use and to expand access to populations everywhere.

WHO’s emergency use licence to Covaxin to accelerate equitable access of vaccine: Bharat Biotech

Bharat Biotech, the Covaxin manufacturer, has been submitting data to the WHO on a rolling basis and submitted additional information at WHO’s request on September 27.

WHO experts reviewed the information available and Bharat Biotech was learnt to have addressed most of the queries raised by the world body.

Covaxin is an indigenous Indian Covid shot, developed and produced here in private-public partnership by Biotech and ICMR.

The Technical Advisory Group for Emergency Use Listing is an independent advisory group that provides a recommendation to WHO whether an unlicensed vaccine can be recommended for emergency use under the EUL procedure, and if so, under what conditions. https://t.co/xzqOHjOVCb

— World Health Organization (WHO) (@WHO) November 3, 2021

Join Whatsapp Channel of The Tribune for latest updates.